EUVIMEDOdkrijte EUVIMED
ÜbersichtsarbeitSystematische ÜbersichtMetaanalyseOpen access

SGLT2 Inhibitors in Autosomal Dominant Polycystic Kidney Disease: A Systematic Review and Meta-Analysis

Ayoub Tantush, Bahaeddin Ben Hamida, Malek Sagher, Nadia Afsheen, Motasem Sager, Allaeddin Abusbaeh, Marwan Tantoush, Ali Abusbaeh, Abdelrahman Najaim, Mohammed Alhamadi, Mohamed Hesham Gamal, Mohamad M Alemam and 1 more

Cureus · 2026-04-24

DOI: 10.7759/cureus.107653 ↗

At a glance

Übersichtsarbeit in Cureus, published on 2026-04-24. Written by Ayoub Tantush and 12 co-authors. Institution: General Medicine, University Hospitals Birmingham NHS Foundation Trust, Birmingham, GBR. Cited 1 times so far (Crossref); 30 references. The full text is freely available in PubMed Central.

PovzetekSubjectsBibliografski podatkiCiteRelated studies

Abstract (original language)

Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disorder, with tolvaptan remaining the primary disease-modifying therapy. SGLT2 inhibitors have demonstrated robust renoprotection across the chronic kidney disease (CKD) spectrum, yet patients with ADPKD have been systematically excluded from pivotal trials due to concerns over vasopressin-mediated cystogenesis. This systematic review and meta-analysis aimed to pool available evidence on SGLT2 inhibitor use in patients with ADPKD. This systematic review and meta-analysis were registered with PROSPERO (CRD420261324155) and conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta‑Analyses (PRISMA) guidelines. Five databases were searched through February 2026 for studies including ADPKD patients receiving any SGLT2 inhibitor. Quality was assessed using the Risk of Bias 2 (RoB2), Newcastle-Ottawa Scale, and Joanna Briggs Institute (JBI) tools, depending on the study design. Eight studies encompassing 3,180 patients were included, comprising one randomized controlled trial (RCT), one target trial emulation study, and six retrospective observational studies. In comparative analyses, SGLT2 inhibitor use was associated with a statistically significant attenuation of estimated glomerular filtration rate (eGFR) decline (pooled mean difference {MD}: 1.344 mL/min/1.73 m²/year; 95% CI: 0.836-1.852). A significant hemoglobin increase was observed in both comparative (MD: 0.66 g/dL) and single-arm analyses (MD: 0.55 g/dL). Subgroup analyses suggested a greater eGFR benefit in non-diabetic patients, though differences were not statistically significant. Our findings suggest that SGLT2 inhibitors may attenuate eGFR decline and improve hemoglobin in ADPKD, with the initial eGFR dip representing a class effect rather than harm, supporting their prospective evaluation in dedicated randomized trials. These findings should be interpretedwith cuchion the predominantly observational study designs, heterogeneous patient populations.

Subjects

Author keywords

autosomal dominant polycystic kidney diseaseegfrmeta-analysisrenoprotectionsglt2 inhibitors

Authors and institutions

  • General Medicine, University Hospitals Birmingham NHS Foundation Trust, Birmingham, GBR.
  • General Medicine, Heartlands Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, GBR.
  • Internal Medicine, Heartlands Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, GBR.
  • Geriatrics, Heartlands Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, GBR.
  • Internal Medicine, University Hospitals Birmingham NHS Foundation Trust, Birmingham, GBR.
  • General Practice, Calderdale and Huddersfield NHS Foundation Trust, Huddersfield, GBR.

Cite

APA

Tantush, A., Ben Hamida, B., Sagher, M., Afsheen, N., Sager, M., Abusbaeh, A., Tantoush, M., Abusbaeh, A., Najaim, A., Alhamadi, M., Hesham Gamal, M., Alemam, M. M., & Elhady, M. M. (2026). SGLT2 Inhibitors in Autosomal Dominant Polycystic Kidney Disease: A Systematic Review and Meta-Analysis. Cureus. https://doi.org/10.7759/cureus.107653

Vancouver

Tantush A, Ben Hamida B, Sagher M, Afsheen N, Sager M, Abusbaeh A, et al. SGLT2 Inhibitors in Autosomal Dominant Polycystic Kidney Disease: A Systematic Review and Meta-Analysis. Cureus. 2026. doi:10.7759/cureus.107653

BibTeX
@article{Tantush2026,
  author = {Tantush, Ayoub and Ben Hamida, Bahaeddin and Sagher, Malek and Afsheen, Nadia and Sager, Motasem and Abusbaeh, Allaeddin and Tantoush, Marwan and Abusbaeh, Ali and Najaim, Abdelrahman and Alhamadi, Mohammed and Hesham Gamal, Mohamed and Alemam, Mohamad M and Elhady, Mahmoud M},
  title = {SGLT2 Inhibitors in Autosomal Dominant Polycystic Kidney Disease: A Systematic Review and Meta-Analysis},
  journal = {Cureus},
  year = {2026},
  doi = {10.7759/cureus.107653}
}
Start for free →